In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.

The high court found that members of a task force that determines what preventive drugs must be covered can be removed at ...

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic ...

Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Susan Monarez, already acting director of the CDC, said during her confirmation hearing that she sees no causal link between ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...